Regression of idiopathic thrombocytopenic purpura in a patient with eradication of hepatitis C virus by direct-acting antivirals.

Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder that is characterized by antibody-mediated platelet destruction and decreased platelet production. ITP is associated with high morbidity in hepatitis C virus (HCV)-infected patients [1], but the relationship between these diseases is unclear. Although interferon therapy was hampered due to thrombocytopenia, recent direct-acting antiviral (DAA) therapies permit HCV eradication in chronic hepatitis patients with complicated ITP. Here, we report a case of successful regression of ITP following HCV eradication by DAA therapy. This article is protected by copyright. All rights reserved.